Viva Biotech Holdings Valuation
Is VBIZ.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VBIZ.F?
Other financial metrics that can be useful for relative valuation.
|What is VBIZ.F's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does VBIZ.F's PE Ratio compare to its peers?
|Company||PE||Estimated Growth||Market Cap|
MRVI Maravai LifeSciences Holdings
SHC Sotera Health
SYNH Syneos Health
VBIZ.F Viva Biotech Holdings
Price-To-Earnings vs Peers: VBIZ.F is expensive based on its Price-To-Earnings Ratio (24.5x) compared to the peer average (11.3x).
Price to Earnings Ratio vs Industry
How does VBIZ.F's PE Ratio compare vs other companies in the US Life Sciences Industry?
Price to Earnings Ratio vs Fair Ratio
What is VBIZ.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||24.5x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate VBIZ.F's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of VBIZ.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate VBIZ.F's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate VBIZ.F's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.